Number of partners
President and CEO
CEO, Exactis Innovation
The high risks and escalating costs of drug development have made it difficult for early-stage biotech companies to attract financing. That challenge, combined with imminent patent cliffs, has triggered a major restructuring of the global pharmaceutical industry as companies race to decrease risk and become more capital efficient. Through CQDM, Canada has developed proven investment models that are reducing risk through open innovation and collaborative R&D with pharmaceutical companies, early-stage biotech companies, academia and public bodies. This allows companies to move beyond a fee-for-service model, retain equity and ownership of their intellectual property, and grow their operations in Canada.
CQDM is sponsored by nine of the world’s largest pharmaceutical companies (Merck, Pfizer, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Eli Lilly Canada, Janssen, Novartis Pharma Canada and Sanofi Canada) and the governments of Quebec and Canada. It provides critical funding and a neutral ground where pharmaceutical and biotech companies collaborate with academic researchers, graduate students, research institutions, venture capitalists, and governments to accelerate the development and validation of precompetitive research tools and platforms. Nearly 120 top scientists from pharma company sponsors also act as mentors for CQDM projects. This forges strong links between big pharma, small biotech and academic scientists, while ensuring that research is aligned with each company’s needs.
* (formerly known as Quebec Consortium for Drug Discovery)